Bisbenzamidines as Antifungal Agents. Are Both Amidine Functions Required to Observe an Anti-Pneumocystis carinii Activity?

Abstract

A library of 19 novel 4-(4-phenylpiperazine-1-yl)benzamidines has been synthesized and evaluated in vitro against Pneumocystis carinii. Among these compounds, N-ethyl- and N-hexyl-4-(4-phenylpiperazine-1-yl)benzamidines emerged as the most promising compounds, with inhibition percentages at 10.0 µg/mL of 87% and 96%, respectively. Those compounds remained active at 0.1 µg/mL.

1. Introduction

Pneumocystis jirovecii pneumonia is a fungal disease that affects immunodeficient individuals and remains an important cause of mortality in AIDS infected persons [1]. The parasite does not respond to classical antifungal therapy, but it is sensitive to some antiprotozoal medicines [2]. Currently, available anti-Pneumocystis drugs are limited by significant problems of efficacy, toxicity and emerging resistance. Classical treatments to cure the disease include the well-known trimethoprim-sulfamethoxazole association (TMP-SMX; Bactrim^TM, Septra^®), dapsone (Avlosulfon^®), atovaquone (Mepron^®), and pentamidine (NebuPent^®, Pentacarinat^®) (1, Figure 1). Among those medicines, pentamidine remains the most effective drug to cure Pneumocystis pneumonia. However major side effects [1] and a poor bioavailability limit its use.

From a structural point of view, pentamidine (1, Figure 1) can be considered as a bisbenzamidine derivative in which both benzamidine moieties are linked by a highly flexible pentyldioxy chain. The structural simplicity of the molecule and its efficacy have encouraged some laboratories [3,4,5,6] to prepare original analogues with the hope to design more efficient and less toxic agents. In previous work [7,8] we demonstrated that 4, 4’-(1,4-piperazinediyl)bisbenzenecarboximidamide (2, Figure 1) is a promising candidate characterized by an in vitro IC₅₀ of 2.61 µM against P. carinii (the rat-associated specie) and exhibiting no in vitro cytotoxicity. In addition, we observed that the introduction of alkyl substituents on the nitrogen atoms of the amidine functions of 2 could increase up to 1,000 fold the activity of the parent compound [7,8].

The mechanism of action of pentamidine and other bisbenzamidines analogues remains unclear. Because bisbenzamidines were shown to bind to the minor groove of DNA [9,10,11], it was initially thought that the anti-Pneumocystis properties were linked to the parasite replication. However derivatives exhibiting high anti-P. carinii activity and a poor affinity for DNA binding have already been identified. A mitochondrial toxicity has been postulated since it has been shown that same bisbenzamidines, including pentamidine, could form complexes with heme [12].

In order to gain insight into Structure Activity Relationships (SAR) of bisbenzamidines, we decided to prepare a library of monobenzamidines structurally related to compound 2 (Figure 2) and to evaluate their biological behavior against P. carinii.

2. Results and Discussion

2.1. Chemistry

The first step in the preparation of such compounds is the nucleophilic displacement of the fluorine atom in 4-fluorobenzonitrile by the secondary amine function of 4-phenylpiperazine in refluxing DMA in the presence of K₂CO₃ as a base (Scheme 1). This step could advantageously be performed in a laboratory microwave oven so that reaction time can be reduced from 5 hours to 60 minutes.

Conversion of the nitrile compound 3 into the amidines 5–23 was effected by the Pinner reaction [13], whereby a solution of compound 3 in dichloromethane saturated with gaseous hydrochloric acid was treated with methanol to afford the imidate intermediate (Scheme 1). This compound was finally reacted with the appropriate amine to give analytically pure amidines.

2.2. Biological evaluation

Table 1. Inhibition percentages of the monobenzamidines against P. carinii.

Compound Number	R	Inhibition % at
		50.0 µg/mL	10.0 µg/mL	0.1 µg/mL
Pentamidine 1		95.0 ± 2.1	92.0 ± 4.5	76.0 ± 4.9
5	H	87.0 ± 4.4	80.0 ± 10.0	23.0 ± 5.0
6		62.0 ± 16.5	56.0 ± 27.6	42.0 ± 12.1
7		83.0 ± 8.6	87.0 ± 27.2	61.0 ± 15.6
8		88.0 ± 7.0	72.0 ± 18.3	48.0 ± 31.3
9		88.0 ± 4.7	90.0 ± 6.9	No activity
10		94.0 ± 1.2	92.0 ± 0.6	28.0 ± 14.6
11		90.0 ± 0.6	94.0 ± 0.3	13.0 ± 16.5
12		96.0 ± 0.6	91.0 ± 0.6	No activity
13		97.0 ± 0.6	92.0 ± 1.1	No activity
14		97.0 ± 1.5	93.0 ± 4.9	43.0 ± 3.2
15		91.0 ± 7.5	96.0 ± 0.6	56.0 ± 2.6
16		92.0 ± 2.6	90.0 ± 4.0	No activity
17		80.0 ± 16.0	93.0 ± 4.3	No activity
18		85.0 ± 12.5	79.0 ± 9.7	No activity
19		93.0 ± 4.1	91.0 ± 1.4	No activity
20		95.0 ± 2.1	94.0 ± 1.15	No activity
21		95.0 ± 2.5	96.0 ± 2.3	No activity
22		73.0 ± 4.5	70.0 ±9.0	No activity
23		96.0 ± 1.5	69.0 ± 7.6	No activity
2		59.0 ± 4.5	66.0 ± 7.5	32.0 ± 7.0

contains the results of the in vitro evaluation of pentamidine 1, compound 2, and the benzamidines 5-23 against P. carinii. Analysis of the data indicated that all compounds retain an antifungal activity at a concentration of 10 µg/mL, with inhibition percentage ranging from 56% to 96%.

At a low concentration of 0.1 µg/mL, the results are more contrasted. At that concentration, the data suggest that the activity was dramatically dependent on the nature of the substituent on the amidine function, as previously described in the bisbenzamidine series [3,4]. In particular, we observed that the presence of an arylalkyl substituent on the amidine function (compounds 19-23) led to a loss of the antifungal activity. Among the other derivatives, the most active compounds were those bearing a linear alkyl group of 1, 2, 3, or 6 carbon atoms (compounds 6-8; 15). Whereas piperazine-1,4-bisbenzamidine (compound 2) and most of its N-alkyl substituted congeners previously studied were at least as efficient as pentamidine (compound 1), the situation is a little bit different in the monobenzamidine series described in the present work. Indeed, all derivatives are less active than pentamidine. Starting from the unsubstituted compound, introduction of an alkyl chain of increasing length on the amidine function leads to a modulation of the anti-Pneumocystis activity, with a maximum of activity observed in the case of ethyl and hexyl substituents. Interestingly, compounds bearing an alkyl chain constituted by 7, 8, or 12 carbon atoms are not active against the fungus, contrary to the bisbenzamidine series. Mention should also be made that in the bisbenzamidine series as well as in the monobenzamidine series, the N-hexyl substituted candidates emerged among the most promising substances. That can tentatively be attributed to a favorable compromise between the hydrophilic properties of the amidine function(s) and the lipophilic character of the alkyl chain(s).

Contrary to the observation made in the bisbenzamidine series, the substitution of the amidines group by an alkyl ramified chain led to a loss of the antifungal activity, except for the analogue bearing a 1-ethylpropyl substituent.

3. Experimental

3.1. General

¹H-NMR spectra were obtained using a Bruker AMX instrument (300 MHz), chemical shifts (δ) are given in ppm using TMS as internal reference. The following abbreviations are used: br for broad, s for singlet, d for doublet, t for triplet, q for quadruplet, and m for multiplet. IR spectra were recorded on a Perkin-Elmer FTIR 1760K. Microwave synthesis were performed in a Milestone Multisynth® oven. Solvents, reagents, and pentamidine (1) were commercially available (Aldrich, Alfa Aesar, Acros Organics) and were used without further purification. Compounds 2 [14] and 3 [15] have been described in the literature. Elemental analyses were performed at the Centre Wallon de Recherches Agronomiques (Libramont-Chevigny, Belgium) or at the Laboratoire de Microanalyse Organique of the Institut des Sciences Appliqués de Rouen (France).

3.2. General procedure for the preparation of compound 3 under microwave irradiation

A mixture of 4-fluorobenzonitrile (2.5 mmol; 0.30 g) and 1-phenylpiperazine (2.5 mmol; 0.38 mL; 0.41 gr) in DMA (2.50 mL) in the presence of K₂CO₃ (2.5 mmol; 0.35 g) was heated 60 minutes at 140 °C in a Multisynth® oven (Milestone) operating at 300 watts. After cooling, the solution was poured into ice cold water and the precipitate was filtered and washed with water and ethanol.

3.3. General procedure for the preparation of compounds 4–23

A mixture of 4-(4-phenylpiperazine-1-yl)benzonitrile (3, 10 mmol, 2.66 g) in dichloromethane (250 mL) and methanol (25 mL) was saturated with HCl gas and the reaction medium was left at room temperature for 24 hours. The precipitate was filtered and thoroughly washed with ether. Without further purification the crude imidate 4 (3 mmol, 1.0 g) was treated with the appropriate amine in refluxing methanol for 1 hour. A precipitate was obtained either by cooling or by addition of ether.

4-(4-Phenylpiperazine-1-yl)benzenecarboximidamide hydrochloride salt (5). Prepared by treatment of the crude imidate 4 with ammonia (15 mmol, 2.5 mL of a 7 N methanolic solution) in refluxing ethanol (10 mL) for 1 hour. The precipitate obtained after cooling was filtered and washed with ether and water. Yield: 64%. M.p.: >300 °C; ¹H-NMR (DMSO-d₆): 9.2 (br, 2H), 9.0 (br, 2H), 7.8 (d, 2H, J = 9 Hz), 7.3 (t, 2H, J = 7 Hz), 7.1 (d, 2H, J = 9 Hz), 7.0 (d, 2H, J = 7 Hz), 6.8 (t, 1H, J = 7 Hz), 3.5 (t, 4H, J = 5 Hz), 3.3 (t, 4H, J = 5 Hz) ppm; IR: 3,073, 2,834, 1,658, 1,607, 1,698, 1,494 cm^-1; C₁₇H₂₀N₄·HCl (316.15). Calc.: C, 63.68; H, 6.63; N, 17.47. Found: C, 64.03; H, 6.23; N, 17.37.

N-Methyl 4-(4-phenylpiperazine-1-yl)benzenecarboximidamide hydrochloride salt (6). Prepared by treatment of the crude compound 4 with methylamine (15 mmol, 1.8 mL of an ethanolic solution at 33%) in ethanol (10 mL) at reflux for 1 hour. After cooling, the precipitate obtained by addition of ether was filtered and washed with water. Yield: 57%. M.p.: >300 °C; ¹H-NMR (DMSO-d₆): 9.7 (br, 1H), 9.3 (br, 1H), 9.0 (br, 1H), 7.8 (d, 2H, J = 9 Hz), 7.3 (t, 2H, J = 7 Hz), 7.1 (d, 2H, J = 9 Hz), 7.0 (d, 2H, J = 7 Hz), 6.8 (t, 1H, J = 7 Hz), 3.5 (t, 4H, J = 5 Hz), 3.3 (t, 4H, J = 5 Hz), 3.0 (s, 3H) ppm; IR: 3,441, 3,056, 1,666, 1,505, 1,446, 1,367, 1,236 cm^-1; C₁₈H₂₂N₄·HCl (330.16). Calc.: C, 65.34; H, 7.01; N, 16.93. Found: C, 65.52; H, 6.99; N, 16.96.

N-Ethyl 4-(4-phenylpiperazine-1-yl)benzenecarboximidamide hydrochloride salt (7). Prepared by treatment of the crude imidate 4 with ethylamine (15 mmol, 7.5 mL of a 2 M methanolic solution) in refluxing methanol (10 mL) for 1 hour. After cooling, the precipitate obtained by addition of ether was filtered and washed with water. Yield: 47%. M.p.: 280–284 °C; ¹H- NMR (DMSO-d₆): 8.8 (br, 3H), 7.8 (d, 2H, J = 9 Hz), 7.3 (t, 2H, J = 7 Hz), 7.1 (d, 2H, J = 9 Hz), 7.0 (d, 2H, J = 7 Hz), 6.8 (t, 1H, J = 7 Hz), 3.5 (t, 4H, J = 5 Hz), 3.4 (q, 2H, J = 7 Hz), 3.3 (t, 4H, J = 5 Hz), 1.2 (t, J = 7 Hz, 3H) ppm; IR: 3,051, 2,840, 1,672, 1,604, 1,505, 1,387, 1,235 cm^-1; C₁₉H₂₄N₄·HCl (344.18). Calc.: C, 66.17; H, 7.31; N, 16.25. Found: C, 65.87; H, 7.27; N, 15.99.

N-Propyl 4-(4-phenylpiperazine-1-yl)benzenecarboximidamide hydrochloride salt (8). Prepared by treatment of the crude imidate 4 with propylamine (15 mmol, 1.2 mL) in refluxing ethanol (10 mL) for 1 hour. The precipitate obtained after cooling was filtered and washed with ether and water. Yield: 53%. M.p.: 275–280 °C; ¹H-NMR (DMSO-d₆): 9.3 (br, 3H), 7.8 (d, 2H, J = 9 Hz), 7.3 (t, 2H, J = 7 Hz), 7.1 (d, 2H, J = 9 Hz), 7.0 (d, 2H, J = 7 Hz), 6.8 (t, 1H, J = 7 Hz), 3.5 (t, 4H, J = 5 Hz), 3.4 (q, 2H, J = 7 Hz), 3.3 (t, 4H, J = 5 Hz), 1.7 (m, 2H, J = 7 Hz), 0.9 (t, 3H, J = 7 Hz); IR: 3,052, 2,970, 2,872, 1,670, 1,505, 1,452, 1,361, 1,234 cm^-1; C₂₀H₂₆N₄·HCl (358.19). Calc.: C, 66.93; H, 7.58; N, 15.61. Found: C, 66.99; H, 7.33; N, 15.39.

N-Isopropyl 4-(4-phenylpiperazine-1-yl)benzenecarboximidamide hydrochloride salt (9). Prepared by treatment of the crude imidate 4 with isopropylamine (15 mmol, 1.3 mL) in refluxing ethanol (10 mL) for 1 hour. After cooling, the precipitate obtained by addition of ether was filtered and washed with water. Yield: 67%. M.p.: >300 °C; ¹H-NMR (DMSO-d₆): 8.7 (br, 3H), 7.8 (d, 2H, J = 9 Hz), 7.3 (t, 2H, J = 7 Hz), 7.1 (d, 2H, J = 9 Hz), 7.0 (d, 2H, J = 7 Hz), 6.8 (t, 1H, J = 7 Hz), 4.1 (m, 1H, J = 7 Hz), 3.5 (t, 4H, J = 5 Hz), 3.3 (t, 4H, J = 5 Hz), 1.3 (d, 6H, J = 5 Hz); IR: 3,410, 3,051, 2,971, 1,666, 1,601, 1,505, 1,385, 1,234 cm^-1; C₂₀H₂₆N₄·HCl (358.19). Calc.: C, 66.93; H, 7.58; N, 15.61. Found: C, 67.02; H, 7.63; N, 15.57.

N-Butyl 4-(4-phenylpiperazine-1-yl)benzenecarboximidamide hydrochloride salt (10). Prepared by treatment of the crude imidate 4 with butylamine (15 mmol, 1.3 mL) in refluxing ethanol (10 mL) for 1 hour. After cooling, the precipitate obtained by addition of ether was filtered and washed with water. Yield: 32%. M.p.: 280–284 °C; ¹H-NMR (DMSO-d₆): 9.3 (br, 3H), 7.8 (d, 2H, J = 9 Hz), 7.3 (t, 2H, J = 7 Hz), 7.1 (d, 2H, J = 9 Hz), 7.0 (d, 2H, J = 7 Hz), 6.8 (t, 1H, J = 7 Hz), 3.5 (t, 4H, J = 5 Hz), 3.4 (t, 2H, J = 7 Hz), 3.3 (t, 4H, J = 5 Hz), 1.6 (m, 2H, J = 7 Hz), 1.4 (m, 2H, J = 7 Hz), 0.9 (t, 3H, J = 7 Hz); IR: 3,229, 3,091, 2,951, 1,665, 1,614, 1,520, 1,497, 1,386, 1,225 cm^-1; C₂₁H₂₈N₄·HCl (372.21). Calc.: C, 67.63; H, 7.84; N, 15.02. Found: C, 67.59; H, 7.85; N, 15.03.

N-Pentyl 4-(4-phenylpiperazine-1-yl)benzenecarboximidamide hydrochloride salt (11). Prepared by treatment of the crude imidate 4 with pentylamine (15 mmol, 1.7 mL) in refluxing ethanol (10 mL) for 1 hour. After cooling, the precipitate obtained by addition of ether was filtered and washed with water. Yield: 30%. M.p.: 285–290 °C. ¹H NMR (DMSO-d₆): 9.3 (br, 3H), 7.7 (d, 2H, J = 9 Hz), 7.3 (t, 2H, J = 7 Hz), 7.1 (d, 2H, J = 9 Hz), 7.0 (d, 2H, J = 7 Hz), 6.8 (t, 1H, J = 7 Hz), 3.5 (t, 4H, J = 5 Hz), 3.4 (t, 2H, J = 7 Hz), 3.3 (t, 4H, J = 5 Hz), 1.6 (m, 2H, J = 7 Hz), 1.3 (m, 4H), 0.9 (t, 3H, J = 7 Hz). IR: 3063, 2957, 2857, 1662, 1603, 1505, 1451, 1386, 1336, 1231 cm^-1. C₂₂H₃₀N₄·1.2 HCl (386,22). Calc.: C, 67.02; H, 7.98; N, 14.21. Found: C, 66.88; H, 8.04; N, 14.45.

N-(3-Methylbutyl)l 4-(4-phenylpiperazine-1-yl)benzenecarboximidamide hydrochloride salt (12). Prepared by treatment of the crude imidate with 3-methylbutylamine (15 mmol, 1.7 mL) in refluxing ethanol (10 mL) for 1 hour. After cooling, the precipitate obtained by addition of ether was filtered and washed with water. Yield: 63%. M.p.: >300 °C; ¹H-NMR (DMSO-d₆): 9.3 (br, 3H), 7.8 (d, 2H, J = 9 Hz), 7.3 (t, 2H, J = 7 Hz), 7.1 (d, 2H, J = 9 Hz), 7.0 (d, 2H, J = 7 Hz), 6.8 (t, 1H, J = 7 Hz), 3.5 (t, 4H, J = 5 Hz), 3.4 (t, 2H, J = 7 Hz), 3.3 (t, 4H, J = 5 Hz), 1.7 (m, 1H), 1.6 (m, 2H), 0.9 (d, 6H, J = 7 Hz); IR: 3,063, 2,957, 2,857, 1,662, 1,603, 1,505, 1,451, 1,386, 1,336, 1,231 cm^-1; C₂₂H₃₀N₄·HCl (386.22). Calc.: C, 68.28; H, 8.07; N, 14.48. Found: C, 68.08; H, 7.84; N, 14.22.

N-(2-Methylbutyl)l 4-(4-phenylpiperazine-1-yl)benzenecarboximidamide hydrochloride salt (13). Prepared by treatment of the crude imidate 4 with 2-methylbutylamine (15 mmol, 1.8 mL) in refluxing ethanol (10 mL) for 1 hour. The precipitate obtained after cooling was filtered and washed with ether and water. Yield: 35%. M.p.: >300 °C; ¹H-NMR (DMSO-d₆): 9.3 (br, 3H), 7.8 (d, 2H, J = 9 Hz), 7.3 (t, 2H, J = 7 Hz), 7.1 (d, 2H, J = 9 Hz), 7.0 (d, 2H, J = 7 Hz), 6.8 (t, 1H, J = 7 Hz), 3.5 (t, 4H, J = 5 Hz), 3.4 (d, 2H, J = 7 Hz), 3.3 (t, 4H, J = 5 Hz), 1.8 (m, 1H), 1.2 (m, 2H), 0.9 (t, 3H, J = 7 Hz), 0.9 (d, 3H, J = 6 Hz); IR: 3,024, 2,960, 2,844, 1,671, 1,604, 1,515, 1,450, 1,387, 1,230 cm^-1; C₂₂H₃₀N₄·1.1 HCl (386.22). Calc.: C, 67.65; H, 8.03; N, 14.34. Found: C, 67.44; H, 7.80; N, 14.11.

N-(1-Ethylpropyl) 4-(4-phenylpiperazine-1-yl)benzenecarboximidamide hydrochloride salt (14). Prepared by treatment of the crude imidate 4 with 1-ethylpropylamine (15 mmol, 1.8 mL) in refluxing ethanol (10 mL) for 1 hour. The precipitate obtained after cooling was filtered and washed with ether and water. Yield: 61%. M.p.: >300 °C; ¹H-NMR (DMSO-d₆): 9.3 (br, 3H), 7.8 (d, 2H, J = 9 Hz), 7.3 (t, 2H, J = 7 Hz), 7.1 (d, 2H, J = 9 Hz), 7.0 (d, 2H, J = 7 Hz), 6.8 (t, 1H, J = 7 Hz), 3.8 (m, 1H), 3.5 (t, 4H, J = 5 Hz), 3.3 (t, 4H, J = 5 Hz), 1.6 (m, 4H), 0.9 (t, 6H, J = 7 Hz); IR: 3,074, 2,966, 2,935, 2,880, 1,666, 1,600, 1,505, 1,231 cm^-1; C₂₂H₃₀N₄·HCl (386.22). Calc.: C, 68.28; H, 8.07; N, 14.48. Found: C, 68.15; H, 8.08; N, 14.46.

N-Hexyl 4-(4-phenylpiperazine-1-yl)benzenecarboximidamide hydrochloride salt (15). The compound was prepared by treatment of the crude imidate 4 with hexylamine (15 mmol, 2.0 mL) in refluxing ethanol (10 mL) for 1 hour. The precipitate obtained after cooling was filtered and washed with ether and water. Yield: 42%. M.p.: 285–290 °C; ¹H-NMR (DMSO-d₆): 9.3 (br, 3H), 7.7 (d, 2H, J = 9 Hz), 7.3 (t, 2H, J = 7 Hz), 7.1 (d, 2H, J = 9 Hz), 7.0 (d, 2H, J = 7 Hz), 6.8 (t, 1H, J = 7 Hz), 3.5 (t, 4H, J = 5 Hz), 3.4 (t, 2H, J = 7 Hz), 3.3 (t, 4H, J = 5 Hz), 1.6 (m, 2H, J = 7 Hz), 1.3 (m, 6H), 0.9 (t, 3H, J = 7 Hz); IR: 3,050, 2,956, 2,931, 1,669, 1,505, 1,451, 1,387, 1,232 cm^-1; C₂₃H₃₂N₄·1.1 HCl (400.24). Calc.: C, 68.27; H, 8.25; N, 13.85. Found: C, 68.31; H, 8.19; N, 13.98.

N-Heptyl 4-(4-phenylpiperazine-1-yl)benzenecarboximidamide hydrochloride salt (16). Prepared by treatment of the crude imidate 4 with heptylamine (15 mmol, 2.2 mL) in refluxing ethanol (10 mL) for 1 hour. After cooling, the precipitate obtained by addition of ether was filtered and washed with water. Yield: 43%. M.p.: 290–294 °C; ¹H-NMR (DMSO-d₆): 9.3 (br, 3H), 7.7 (d, 2H, J = 9 Hz), 7.3 (t, 2H, J = 7 Hz), 7.1 (d, 2H, J = 9 Hz), 7.0 (d, 2H, J = 7 Hz), 6.8 (t, 1H, J = 7 Hz), 3.5 (t, 4H, J = 5 Hz), 3.4 (t, 2H, J = 7 Hz), 3.3 (t, 4H, J = 5 Hz), 1.6 (m, 2H, J = 7 Hz), 1.3 (m, 8H), 0.9 (t, 3H, J = 7 Hz); IR: 3,078, 2,956, 2,926, 1,661, 1,505, 1,387, 1,387, 1,234 cm^-1; C₂₄H₃₄N₄·1.1 HCl (414.26). Calc.: C, 68.85; H, 8.45; N, 13.38. Found: C, 69.20; H, 8.09; N, 13.47.

N-Octyl 4-(4-phenylpiperazine-1-yl)benzenecarboximidamide hydrochloride salt (17). Prepared by treatment of the crude imidate 4 with octylamine (15 mmol, 2.5 mL) in refluxing ethanol (10 mL) for 1 hour. The precipitate obtained after cooling was filtered and washed with ether and water. Yield: 43%. M.p.: 280–284 °C; ¹H-NMR (DMSO-d₆): 9.3 (br, 3H), 7.7 (d, 2H, J = 9 Hz), 7.3 (t, 2H, J = 7 Hz), 7.1 (d, 2H, J = 9 Hz), 7.0 (d, 2H, J = 7 Hz), 6.8 (t, 1H, J = 7 Hz), 3.5 (t, 4H, J = 5 Hz), 3.4 (t, 2H, J = 7 Hz), 3.3 (t, 4H, J = 5 Hz), 1.6 (m, 2H, J = 7 Hz), 1.3 (m, 10H), 0.9 (t, 3H, J = 7 Hz); IR: 3,062, 2,923, 2,853, 1,662, 1,607, 1,505, 1,386, 1,232 cm^-1; C₂₅H₃₆N₄·HCl (428.27). Calc.: C, 69.99; H, 8.69; N, 13.06. Found: C, 69.94; H, 8.68; N, 13.04.

N-Dodecyl 4-(4-phenylpiperazine-1-yl)benzenecarboximidamide hydrochloride salt (18). Prepared by treatment of the crude imidate 4 with dodecylamine (15 mmol, 3.5 mL) in refluxing ethanol (10 mL) for 1 hour. The precipitate obtained after cooling was filtered and washed with ether and water. Yield: 51%. M.p.: 275–280 °C; ¹H-NMR (DMSO-d₆): 9.3 (br, 3H), 7.7 (d, 2H, J = 9 Hz), 7.3 (t, 2H, J = 7 Hz), 7.1 (d, 2H, J = 9 Hz), 7.0 (d, 2H, J = 7 Hz), 6.8 (t, 1H, J = 7 Hz), 3.5 (t, 4H, J = 5 Hz), 3.4 (t, 2H, J = 7 Hz), 3.3 (t, 4H, J = 5 Hz), 1.6 (m, 2H, J = 7 Hz), 1.4 (m, 18H), 0.9 (t, 3H, J = 7 Hz); IR: 3,047, 2,920, 2,850, 1,668, 1,608, 1,515, 1,466, 1,387, 1,233 cm^-1; C₂₉H₄₄N₄·HCl (484.33). Calc.: C, 71.79; H, 9.35; N, 11.55. Found: C, 71.77; H, 9.34; N, 11.57.

N-Benzyl 4-(4-phenylpiperazine-1-yl)benzenecarboximidamide hydrochloride salt (19). Prepared by treatment of the crude imidate 4 with benzylamine (15 mmol, 1.6 mL) in refluxing ethanol (10 mL) for 1 hour. After cooling, the precipitate obtained by addition of ether was filtered and washed with water. Yield: 67%. M.p.: 290–295 °C; ¹H-NMR (DMSO-d₆): 9.3 (br, 3H), 7.7 (d, 2H, J = 8 Hz), 7.4 (m, 5H), 7.3 (t, 2H, J = 7 Hz), 7.1 (d, 2H, J = 8 Hz), 7.0 (d, 2H, J = 7 Hz), 6.8 (t, 1H, J = 7 Hz), 4.7 (s, 2H), 3.5 (t, 4H, J = 5 Hz), 3.3 (t, 4H, J = 5 Hz); IR: 3,033, 2,359, 1,665, 1,516, 1,497, 1,452, 1,388, 1,230 cm^-1; C₂₄H₂₆N₄·HCl (406.19). Calc.: C, 70.83; H, 6.69; N, 13.77. Found: C, 70.77; H, 6.66; N, 13.76.

N-Phenethyl 4-(4-phenylpiperazine-1-yl)benzenecarboximidamide hydrochloride salt (20). Prepared by treatment of the crude imidate 4 with phenethylamine (15 mmol, 1.9 mL) in refluxing ethanol (10 mL) at for 1 hour. After cooling, the precipitate obtained by addition of ether was filtered and washed with water. Yield: 64%. M.p.: >300 °C; ¹H-NMR (DMSO-d₆): 9.3 (br, 3H), 7.7 (d, 2H, J = 8 Hz), 7.4 (m, 5H), 7.3 (t, 2H, J = 7 Hz), 7.1 (d, 2H, J = 8 Hz), 7.0 (d, 2H, J = 7 Hz), 6.8 (t, 1H, J = 7 Hz), 3.7 (t, 2H, J = 7 Hz), 3.5 (t, 4H, J = 5 Hz), 3.3 (t, 4H, J = 5 Hz), 3.0 (t, 2H, J = 7Hz); IR: 3,051, 1,605, 1,671, 1,498, 1,452, 1,383, 1,231 cm^-1; C₂₅H₂₈N₄·0.8 HCl (420.21). Calc.: C, 72.58; H, 7.02; N, 13.54. Found: C, 72.71; H, 6.89; N, 13.35.

N-(3-Phenylpropyl) 4-(4-phenylpiperazine-1-yl)benzenecarboximidamide hydrochloride salt (21). Prepared by treatment of the crude imidate 4 with 3-phenylpropylamine (15 mmol, 2.1 mL) in reluxing ethanol (10 mL) for 1 hour. After cooling, the precipitate obtained by addition of ether was filtered and washed with water. Yield: 51%. M.p.: 250–255 °C; ¹H-NMR (DMSO-d₆): 9.3 (br, 3H), 7.7 (d, 2H, J = 8 Hz), 7.4 (m, 5H), 7.3 (t, 2H, J = 7 Hz), 7.1 (d, 2H, J = 8 Hz), 7.0 (d, 2H, J = 7 Hz), 6.8 (t, 1H, J = 7 Hz), 3.5 (t, 4H, J = 5 Hz), 3.4 (t, 2H, J = 7 Hz), 3.3 (t, 4H, J = 5 Hz), 2.7 (m, 2H), 1.9 (m, 2H); IR: 3,073, 1,658, 1,607, 1,505, 1,232 cm^-1; C₂₆H₃₀N₄·HCl (434.22). Calc.: C, 71.79; H, 7.18; N, 12.88. Found: C, 71.81; H, 7.2; N, 12.86.

N-(4-Fluorobenzyl) 4-(4-phenylpiperazine-1-yl)benzenecarboximidamide hydrochloride salt (22). Prepared by treatment of the crude imidate 4 with 4-fluorobenzylamine (15 mmol, 1.7 mL) in refluxing ethanol (10 mL) for 1 hour. After cooling, the precipitate obtained by addition of ether was filtered and washed with water. Yield: 58%. M.p.: 280–285 °C; ¹H-NMR (DMSO-d₆): 9.3 (br, 3H), 7.8 (d, 2H, J = 8 Hz), 7.3 (m, 4H), 7.2 (t, 2H, J = 7 Hz), 7.1 (d, 2H, J = 8 Hz), 7.0 (d, 2H, J = 7 Hz), 6.8 (t, 1H, J = 7 Hz), 4.7 (s, 2H), 3.6 (t, 4H, J = 5 Hz), 3.3 (t, 4H, J = 5 Hz); IR: 3,039, 1,666, 1,600, 1,515, 1,385, 1,234 cm^-1; C₂₄H₂₅FN₄·HCl (424.18). Calc.: C, 67.83; H, 6.17; N, 13.18. Found: C, 67.82; H, 6.18; N, 13.17.

N-2-(4-Fluorophenyl)ethyl 4-(4-phenylpiperazine-1-yl)benzenecarboximidamide hydrochloride salt (23). The compound was obtained by treatment of the crude imidate 4 with 2-(4-fluorophenyl)-ethylamine (15 mmol, 2.0 mL) in reluxing ethanol (10 mL) for 1 hour. After cooling, a precipitate was obtained by pouring ether into the solution. The solid was filtered and washed with water. Yield: 64%. M.p.: >300 °C; ¹H-NMR (DMSO-d₆): 9.3 (br, 3H), 7.7 (d, 2H, J = 8 Hz), 7.3 (m, 4H), 7.2 (t, 2H, J = 7 Hz), 7.1 (d, 2H, J = 8 Hz), 7.0 (d, 2H, J = 7 Hz), 6.8 (t, 1H, J = 7 Hz), 3.7 (t, 2H, J = 7 Hz), 3.6 (t, 4H, J = 5 Hz), 3.3 (t, 4H, J = 5 Hz), 3.2 (t, 2H, J = 7 Hz); IR: 3,040, 1,672, 1,604, 1,511, 1,463, 1,452, 1,385, 1,231, 1,206, 1,160 cm^-1; C₂₅H₂₇FN₄·HCl (438.20). Calc.: C, 68.40; H, 6.43; N, 12.76. Found: C, 68.41; H, 6.39; N, 12.79.

3.4. Biological evaluation

To determine the in vitro drug susceptibility of P. carinii, axenic cultures of the organism were produced as follows. All the experiments were carried out in 24-well plates with a final volume of 2 mL of Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% of fetal calf serum containing a final inoculum of 1.0 × 10⁶ organisms per mL. Plates with organisms were incubated for 4 days in an atmosphere of 5% CO₂ at 37 °C. P. carinii was quantitated on air dried smears stained with a rapid panoptic methanol-Giemsa stain (RAL-555), which stains trophic forms, sporocytes and cysts of Pneumocystis. All susceptibility assays were set up in triplicate. The anti-Pneumocystis activity of a single concentration of compound may be expressed in terms of percent inhibition, defined as the decrease (expressed as percentage) in P. carinii forms in antifungal-treated cultures with respect to the total microorganism count in compound-free culture.

4. Conclusions

In summary, a library of 19 monobenzamidines linked on a 4-phenylpiperazine-1-yl scaffold has been synthesized and evaluated in vitro against Pneumocystis carinii. As in a series of bisbenzamidine analogues, the antifungal activity can easily be modulated by the introduction of appropriate alkyl substituents on the amidine function. However at the lowest concentration (0.1 µg/mL) we evaluated those monobenzamidines, only two derivatives (compounds 7 and 15) exhibited a percentage of inhibition on the growth of P. carinii higher than 50 %. Nevertheless the monobenzamidines reported in this work are obviously less active than pentamidine and other bisbenzamidines already tested. That suggests that the presence of both amidine groups are required to observe a marked anti-P. carinii effect.